Author

Anna Ossami Saidy

Observed name: Anna O. Saidy

Institutions: MSB Medical School Berlin, Helios Hospital Berlin-Buch

Observed institutions: MSB Medical School Berlin, Helios Hospital Berlin-Buch

ORCID: 0000-0001-6722-0065

Observed ORCID: 0000-0001-6722-0065

OpenAlex ID: A5093396641

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma

2025 · Evgenii Shumilov, Julia Katharina Scholz, et al. · Blood Advances · 47

PDF

Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study

2024 · Philipp Berning, Evgenii Shumilov, et al. · HemaSphere · 46

PDF

Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma

2025 · Nora Liebers, Ariane Boumendil, et al. · Blood Cancer Discovery · 10

PDF

Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma

2024 · Evgenii Shumilov, Rebecca Wurm-Kuczera, et al. · Blood · 7

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

2023 · Anna Ossami Saidy, Stephan Fuhrmann, et al. · Blood · 5

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real‐world analysis

2025 · Markus Maulhardt, Simon Call, et al. · HemaSphere · 3

PDF

Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

2024 · Yasmina I.M. Serroukh, Mathilde Fekom, et al. · Blood · 3

PDF

Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

2024 · Markus Maulhardt, Philipp Berning, et al. · Blood · 3

Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström's Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)

2024 · Charalampia Kyriakou, Mathilde Fekom, et al. · Blood · 3

PDF

Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article

2026 · Abdulrahman Nasiri, Riad El Fakih, et al. · Bone Marrow Transplantation · 1

PDF

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland – part II – expert based recommendations for surveillance and management of side-effects

2026 · Andreas Ziegler, Claudia Weiß, et al. · Journal of Neuromuscular Diseases · 1

Data from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma

2025 · Nora Liebers, Ariane Boumendil, et al. · 1

Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study

2024 · Philipp Berning, Markus Maulhardt, et al. · Blood · 1

PDF

Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

2024 · Yasmina I.M. Serroukh, Mathilde Fekom, et al. · Blood · 1

Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis

2026 · Evgenii Shumilov, Lina Kolloch, et al. · Blood Advances

PDF

Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study

2026 · Anna Ossami Saidy, Bettina Altmann, et al. · Haematologica

PDF

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)

2026 · Anna Ossami Saidy, Ariane Boumendil, et al. · Bone Marrow Transplantation

Figure S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma